1. Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study.
- Author
-
Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, and Mucke HA
- Subjects
- Aged, Aged, 80 and over, Alzheimer Disease diagnosis, Female, Humans, Male, Prospective Studies, Treatment Outcome, Alzheimer Disease drug therapy, Alzheimer Disease psychology, Memantine therapeutic use, Product Surveillance, Postmarketing methods, Severity of Illness Index
- Abstract
Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.
- Published
- 2011
- Full Text
- View/download PDF